Laurus Lab news:

Laurus Lab on Friday said it has signed an agreement to invest in Immunoadoptive Cell Therapy (ImmunoACT), an IIT-Bombay incubated company that’s developing an indigenous CAR T-cell therapy for curing specific types of blood cancers.

The company will acquire 26.62% stake (fully diluted basis) in ImmunoACT for a cash consideration of approximately ₹46 crore, subject to the fulfilment of certain conditions.

Leave a Reply